Anthocyanin-rich dried fruit consumption increases polyphenol excretion and lowers plasma uric acid in coronary artery disease: a randomized trial.

Nutr Metab Cardiovasc DisApr 2, 2026 (epub)
Clinical ResearchCardiology

Sogand Tavakoli, Fahime Ansarifard, Saeed Alipour Parsa et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized, parallel-group trial assessed an 8-week dried-fruit intervention in patients with coronary artery disease after angioplasty. Participants consumed either control or a daily combination of black raisins, dried sour cherries, and cranberry powder, providing approximately 66 mg of anthocyanins. Among 63 study completers, the intervention increased urinary total polyphenol excretion and reduced plasma uric acid compared with control. Mean uric acid change was 1.2 mg/dL [0.7, 1.8] in the fruit group versus 0.2 mg/dL [-0.3, 0.6] in control (p < 0.01). Other measured cardiometabolic outcomes showed no significant between-group differences.

Key findings

  • Urinary total polyphenol excretion increased substantially in the anthocyanin-rich fruit group compared with control.
  • Plasma uric acid mean change was 1.2 mg/dL [0.7, 1.8] with fruit versus 0.2 mg/dL [-0.3, 0.6] with control (p < 0.01).
  • Uric acid reduction correlated negatively with change in urinary total flavanols (r = -0.351; p < 0.01).
  • There were no significant between-group differences in cholesterol efflux capacity or inflammatory biomarkers; LDL cholesterol showed a non-significant tendency to decrease (p = 0.06).

Why it matters

The findings suggest that a modest intake of anthocyanin-rich dried fruits can alter polyphenol excretion and lower plasma uric acid over eight weeks in people with coronary artery disease. However, the intervention did not significantly improve several other measured cardiometabolic markers, so the results do not establish broader cardiovascular benefit.

What to keep in mind

The study was limited to 63 completers with coronary artery disease after angioplasty and assessed outcomes over eight weeks; it does not establish longer-term effects or clinical cardiovascular outcomes.

Source

Published in Nutr Metab Cardiovasc Dis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.